Anti-GLP-1(7-37) and GLP-1(7-36)amide (N-terminal specific)

Cat.No. ABS 033-04

Cat. No.
ABS 033-04
Product name
Anti-GLP-1(7-37) and GLP-1(7-36)amide (N-terminal specific)
Description
Specificity

ABS 033-04 binds the free N-terminus of GLP-1(7-37) and GLP-1(7-36)amide and shows <0.2% cross-reactivity with GLP-1(1-37), GLP-1(9-36)amide, glucagon, human GIP and exendin-4. Cross-reacts approximately 1% with human GLP-2.

Immunogen

Synthetic GLP-1(7-17) 

Application
Species reactivity (positive)
Human, Mouse
Species reactivity (negative)
Not determined
Subclass

IgG1/k

Gene ID
2641
Clone number
4
Epitope

Free N-terminus of GLP-1(7-37) and GLP-1(7-36)amide.

Content

Available in 200 µL and 1 mL size.1 mg/mL +/- 15%. See Certificate of Analysis for details.

Purification
Protein-A purified
Form
Liquid
Solvent
0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage
4-8ºC without exposure to light. No precautions necessary during handling.
Target

Glucagon-like peptide 1(7-36)amide (GLP-1(7-36)amide) is the principal active form of GLP-1, the other being GLP-1(7-37). GLP-1 is a peptide hormone of the glucagon family, produced by the L cells of the intestinal mucosa from the same prohormone as glucagon. The active forms are potent stimulators of glucose-dependent insulin secretion. The sequence of GLP-1 is fully conserved in all mammalian species examined so far.

Application 1

ELISA
ABS 033-04 binds free GLP-1(7-37) and free GLP-1(7-36)amide. Not recommended for use in sandwich ELISA. (1)

Application 2

IHC
ABS 033-04 can be used in IHC.

Endocrine alpha cells from diabetic mice stained with ABS 033-04 (1:500). Courtesy of Dr. Annette Plesner, University of British Columbia

1. Murphy RE, Kinhikar AG, Shields MJ, Rosario JD, Preston R, Levin N, Ward GH (2010) Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. Journal of Pharmaceutical and Biomedical Analysis 53:221-227.